#Sweden #Immunovia #Lund #pancreatic cancer #Nomination Committee

Immunovia AB Appoints Nomination Committee for 2025 AGM

LUND, Sweden — January 8, 2025 — In a significant move aimed at strengthening its governance, Immunovia AB (Nasdaq Stockholm: IMMNOV), a pioneer in pancreatic cancer diagnostics, has announced the formation of its Nomination Committee. This committee is crucial for leading the nominations for the upcoming Annual General Meeting (AGM) scheduled for May 14, 2025.

Under the guidelines set forth for the Nomination Committee, its structure will comprise four members. Three of these members are appointed by the company’s three largest shareholders, with the fourth member serving as the Chair of the Board of Directors. This arrangement ensures a representation of about 5.65% of the total shares and votes in Immunovia based on the figures reported as of September 30, 2024.

The individuals appointed to the committee include:

• - Christer Køhler (representing Jens Henrik Jensen)
• - Mats Leifland (representing Vincent Saldell)
• - Sara Ek (representing Carl Borrebaeck)
• - Peter Høngaard Andersen, serving as the Chair of the Board.

Notably, Jeff Borcherding, the CEO of Immunovia, chose not to appoint a representative from his substantial shareholding. This decision was made in order to uphold the independence of the Nomination Committee, a move that underscores the company's commitment to governance integrity.

The primary responsibility of the Nomination Committee will be to prepare recommendations for the shareholders regarding board nominations, focusing on ensuring that the skill sets of the board members align with the strategic transition of Immunovia from a research-oriented to a commercial-facing organization in the United States market. Furthermore, the committee will assess and suggest appropriate compensation for the Board members, benchmarked against industry standards. It will also handle nominations and compensation reviews for the auditors of the firm.

Peter Høngaard Andersen, Chair of the Board of Directors, stated, "It’s a pleasure to have the Nomination Committee in place as we gear up for the AGM 2025. The committee's work is vital to make sure our board members reflect the evolving focus of Immunovia from R&D to commercialization in the US market.”

The findings and recommendations of the Nomination Committee will be disclosed in the notice for the Annual General Meeting in May. Shareholders are encouraged to consider these proposals, which aim to enhance Immunovia's corporate governance and strategic positioning in the competitive landscape of pancreatic cancer diagnostics.

For further details regarding the Nomination Committee's principles and responsibilities, stakeholders can visit Immunovia's investor relations website.

About Immunovia AB
Immunovia is a diagnostic innovator committed to improving the survival rates of pancreatic cancer patients through early detection methodologies. Focusing on blood-based tests designed to identify specific proteins and antibodies indicating high-risk patients, Immunovia collaborates with healthcare professionals and patient advocacy groups to ensure accessibility to their vital tests. With approximately 1.8 million high-risk individuals in the USA alone, the potential impact of these diagnostic tools is significant.

For more information, please contact:

• - Jeff Borcherding, CEO
• - Karin Almqvist Liwendahl, CFO

Visit Immunovia for more updates.